



UC Irvine Health

趙 Chao Family
Comprehensive Cancer Center



 **HYUNDAI Cancer Institute**

 **CHOC Children's**

**The Society for Adolescent and Young Adult Oncology (SAYAO),
in conjunction with
The University of California, Irvine and CHOC Children's Hyundai Cancer Institute
2015 Leukemia Meeting:**

**From Pediatric to Adult Acute Lymphoblastic Leukemia:
A Common Strategy for a Cure**

AGENDA

Irvine, California

Organizer/ Moderator:

Leonard Sender, MD

- UC Irvine CFCCC, CHOC Children's Hyundai Cancer Institute

Faculty Leaders:

Mark Litzow, MD

- Chair, Leukemia Committee, Eastern Cooperative Oncology Group (ECOG), Mayo Clinic

Dan Douer, MD

- Memorial Sloan Kettering Cancer Center: Leukemia Program

Susan O'Brien, MD

- UC Irvine Chao Family Comprehensive Cancer Center

Monday October 26th 2105 –Wednesday October 28th 2015

Monday – half day 12:00-17:30

Tuesday- full day 08:00-17:30

Wednesday- half day 08:00-12:00

Monday, 26 October 2015

		Monday, 26 October 2015
12:00-12:30		Registration and Refreshments
12:30-12:45	15min	Introduction and Welcome Leonard Sender, MD
I.		Immuno-Oncology Moderator: Susan O'Brien, MD · UC Irvine CFCCC
12:45-13:45	20min 20min 20min	Bio-Pharmaceutical Company: Clinical Updates <i>Blinotumumab</i> ▪ Industry: Jonathan Benjamin, MD, PhD · AMGEN <i>Inotuzumab Ozogamycin</i> ▪ Industry: Mark Shapiro, MD, PhD · Pfizer <i>Academic Perspective Mark Litzow, MD · ECOG, Mayo Clinic</i>
13:45-14:00	15min	Blinatumumab: Logistics and Toxicity <i>Learning from a Blinotumumab Clinical Program Review of Pediatric and AYA Cases</i> ▪ Sharon Bergeron, RN · Clinical Oncology Educator, CHOC Children's
14:00-15:30	15min 15min 15min 15min 15min 15min	CAR-T Cell Academic Institutions Program Clinical Updates: <i>CAR-T Cells – Novartis/UPENN/CHOP</i> ▪ Shannon Maude, MD · UPENN/ CHOP <i>Kite Pharmaceutical</i> ▪ Rajul Jain · Kite Pharmaceutical <i>NCI Pediatric Branch</i> ▪ Terry Fry, MD · NCI Pediatric Branch <i>CAR-T cells and MSKCC</i> ▪ Jae Park, MD · Memorial Sloan Kettering Cancer Center <i>Juno Therapeutics</i> ▪ Samuel C. Blackman, MD, PhD · <i>Vision for CART therapy in a nationwide trial</i> ▪ Peter Adamson, MD · CHOP / COG
15:30-16:10	40min	Q & A Panel Session
16:10-16:30	20min	BREAK
II.		Drugs and Regimens Moderator: Leonard Sender, MD · UC Irvine, CHOC Children's Hyundai Cancer Institute
16:30-18:30	20min 20min 20min 20min 20min 20min	Newly Diagnosed Patient – Asparaginase Intensive vs. Hyper-CVAD Regimens – Updates ▪ MD Anderson - Hyper-CVAD and Beyond Elias Jabour, MD · MD Anderson ▪ Dana Farber Protocols –Asparaginase-Intensive Adult ALL Dan DeAngelo, MD, PhD · Dana Farber Cancer Institute ▪ MSKCC- Asparaginase-Intensive Adult ALL Dan Douer, MD · Memorial Sloan Kettering Cancer Center ▪ NIH Cooperative Groups –COG, SWOG, Alliance Mark Litzow, MD · ECOG, Mayo Clinic ▪ NOPHO Leukemia Group Kjeld Schmiegelow, MD · Rigshospitalet, Denmark ▪ UK Strategy – Intensive Asparaginase vs other strategies? Nicholas Heaney, MD · Glasgow
18:30-18:45	15min	Salvage Programs: What to offer in a crowded field of new options, what comes first? <i>What about Marqibo? (Liposomal Vincristine)</i> Nirali Shah, MD · NCI Pediatric Branch
18:45-19:25	40min	Q & A Panel Session

		Tuesday, 27 October, 2015
7:00-8:00		BREAKFAST
III.		Minimal/Measurable Residual Disease - Redefining the Definition of Remission in Clinical Trials and its Implications for Therapy Moderator: Jacque Van Dongen, MD, PhD · Univ Medical Center Rotterdam (Erasmus MC)
8:00-9:20	20min 20min 20min 20min	Technology Update: Which Approach, Are They Equivalent? <i>MRD –Overview</i> <ul style="list-style-type: none"> ▪ MRD – Adaptive Biotechnologies- Ilan ‘Lanny’ Kirsch, MD · Adaptive Biotechnologies St Jude Children’s Cancer Research Hospital ▪ Sima Jeha, MD · St. Jude Children’s Research Hospital Integration of MRD into COD Protocols ▪ Michael Loken, PhD · Hematologics, Fred Hutchinson Cancer Research Center ▪ Euro MRD/Flow Jacque Van Dongen, MD, PhD · University Medical Center Rotterdam (Erasmus MC)
9:20-10:20	60min	Q & A Panel Session
10:20-10:40	20min	BREAK
IV.		Clinical Research Trials
10.40-11:10	30min	Evolution of the St Jude’s Leukemia Protocols Ching-Hon Pui, MD · St. Jude Children’s Research Hospital
11:10-11:30	20min	Update: Successor Trial to C10403 Dan DeAngelo, MD, PhD · Dana Farber Cancer Institute
11:30-11:55	25min	Q & A Panel Session
11:55-13:00	65min	LUNCH
V.		Asparaginase
13:00-14:00	20min 20min 20min	Moderator: Dan Douer, MD · Memorial Sloan Kettering Cancer Center Panel: Mary Relling, PharmD · St. Jude Children’s Research Hospital Paul Gaynon, MD · Children’s Hospital Los Angeles William Evans, PharmD · St. Jude Children’s Research Hospital
14:00-14:20	20min	Asparaginase substitution influence in the GRAALL trial, monitoring asparaginase activity and immunization in adult patients. Nicolas Boissel, MD, PhD · Hopital Saint-Louis-University Paris 7, France
14:20-15:20	60min	Q & A
15:20-15:40	20min	BREAK
VI.		Hematopoietic Stem Cell Transplantations
15:40-16:20	20min 20min	Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) Bipin Savani, MD · Vanderbilt Ingram Cancer Center Paul Richardson, MD · Dana-Farber Cancer Institute
16:20-17:00	40min	Q & A
19:30		Dinner

Wednesday, 28 October, 2015		
7:00-8:00		Breakfast – Beckman Center
VII.		Genomics
8:00-9:20	15min	mTOR inhibition enhances cytotoxic effects of TKIs in Ph-like B-ALL David Fruman, PhD · University of California, Irvine
	15min	Do these new genomics insights translate to the clinic? Rick van Etten, MD, PhD · UC Irvine CFCCC
	15min	Charles Mullighan, MBBS(Hons), MSc, MD · St. Jude Children's Research Hospital
	15min	Kajsa Paulsson, PhD · Lund University, Sweden
	20min	Infant ALL with MLL-AF4 fusion Tanja Gruber, MD, PhD · St. Jude Children's Research Hospital
9:20-9:55	35min	Q & A
VIII.		Unique Population Biology
9:55-10:35	20min	Evolutionary genetics and update on unique biology of Hispanic leukemia population: Implications for treatment interventions Juan Manuel Mejia-Arangur�, MD · Unidad Medica de Alta Especialidad, Mexico City
	20min	Jun Yang, PhD · St. Jude Children's Research Hospital
10:35-10:45	10min	Break
IX.		Philadelphia Positive Acute Leukemia
10:45-11:15	15min	Update – pediatrics vs. adult approach Kirk Schultz, MD · University of British Columbia
	15min	MD Anderson Experience with HyperCVAD and Ponatinib Elias Jabbour, MD · MD Anderson Cancer Center
11:15-11:45	30min	Q & A
X.		Summation
11:45-12:00	15min	Concluding Remarks Archie Blyer, MD

(rev 9/21/2015)